Title 21Food and DrugsRelease 119-73not60

§814 Removal of Exemption of Certain Drugs

Title 21 › Chapter 13— DRUG ABUSE PREVENTION AND CONTROL › Subchapter I— CONTROL AND ENFORCEMENT › Part B— Authority To Control; Standards and Schedules › § 814

Last updated Apr 5, 2026|Official source

Summary

The Attorney General must make rules to remove a drug or group of drugs from a special exemption when they find people are using those drugs to get a listed chemical for making illegal drugs. In deciding to remove an exemption, the Attorney General will look at three things: how big, long, and important the diversion is; whether the drug is made so it can't easily be used for making illegal drugs; and whether the listed chemical can be easily taken out. The removal should target only the specific type of drug showing diversion unless there is evidence the problem will spread to others. A manufacturer can ask the Attorney General to put the exemption back for a particular product if the company shows it stops diversion. The Attorney General will consider package size and packaging, how the product is sold and advertised, any evidence of diversion, steps the manufacturer took to prevent diversion, and other health and safety factors. If the manufacturer files a real application within 60 days after the removal rule, sales of that product while the application is pending (and for 60 days after a denial) are not treated as regulated, unless the Attorney General finds diversion and tells the applicant. The Attorney General can later change or cancel a reinstated exemption if diversion starts again or key data change.

Full Legal Text

Title 21, §814

Food and Drugs — Source: USLM XML via OLRC

(a)The Attorney General shall by regulation remove from exemption under section 802(39)(A)(iv) of this title a drug or group of drugs that the Attorney General finds is being diverted to obtain a listed chemical for use in the illicit production of a controlled substance.
(b)In removing a drug or group of drugs from exemption under subsection (a), the Attorney General shall consider, with respect to a drug or group of drugs that is proposed to be removed from exemption—
(1)the scope, duration, and significance of the diversion;
(2)whether the drug or group of drugs is formulated in such a way that it cannot be easily used in the illicit production of a controlled substance; and
(3)whether the listed chemical can be readily recovered from the drug or group of drugs.
(c)The Attorney General shall limit the designation of a drug or a group of drugs removed from exemption under subsection (a) to the most particularly identifiable type of drug or group of drugs for which evidence of diversion exists unless there is evidence, based on the pattern of diversion and other relevant factors, that the diversion will not be limited to that particular drug or group of drugs.
(d)(1)On application by a manufacturer of a particular drug product that has been removed from exemption under subsection (a), the Attorney General shall by regulation reinstate the exemption with respect to that particular drug product if the Attorney General determines that the particular drug product is manufactured and distributed in a manner that prevents diversion.
(2)In deciding whether to reinstate the exemption with respect to a particular drug product under paragraph (1), the Attorney General shall consider—
(A)the package sizes and manner of packaging of the drug product;
(B)the manner of distribution and advertising of the drug product;
(C)evidence of diversion of the drug product;
(D)any actions taken by the manufacturer to prevent diversion of the drug product; and
(E)such other factors as are relevant to and consistent with the public health and safety, including the factors described in subsection (b) as applied to the drug product.
(3)A transaction involving a particular drug product that is the subject of a bona fide pending application for reinstatement of exemption filed with the Attorney General not later than 60 days after a regulation removing the exemption is issued pursuant to subsection (a) shall not be considered to be a regulated transaction if the transaction occurs during the pendency of the application and, if the Attorney General denies the application, during the period of 60 days following the date on which the Attorney General denies the application, unless—
(A)the Attorney General has evidence that, applying the factors described in subsection (b) to the drug product, the drug product is being diverted; and
(B)the Attorney General so notifies the applicant.
(4)A regulation reinstating an exemption under paragraph (1) may be modified or revoked with respect to a particular drug product upon a finding that—
(A)applying the factors described in subsection (b) to the drug product, the drug product is being diverted; or
(B)there is a significant change in the data that led to the issuance of the regulation.

Legislative History

Notes & Related Subsidiaries

Editorial Notes

Amendments

2006—Subsec. (e). Pub. L. 109–177 struck out subsec. (e). Text read as follows: “Pursuant to subsection (d)(1) of this section, the Attorney General shall by regulation reinstate the exemption with respect to a particular ephedrine, pseudoephedrine, or phenylpropanolamine drug product if the Attorney General determines that the drug product is manufactured and distributed in a manner that prevents diversion. In making this determination the Attorney General shall consider the factors listed in subsection (d)(2) of this section. Any regulation issued pursuant to this subsection may be amended or revoked based on the factors listed in subsection (d)(4) of this section.” 1996—Subsec. (e). Pub. L. 104–237 added subsec. (e).

Statutory Notes and Related Subsidiaries

Effective Date

of 1996 AmendmentAmendment by Pub. L. 104–237 not applicable to sale of any pseudoephedrine or phenylpropanolamine product prior to 12 months after Oct. 3, 1996, except that, on application of manufacturer of particular drug product, Attorney General may exercise sole and judicially unreviewable discretion to extend such

Effective Date

up to additional 6 months, see section 401(g) of Pub. L. 104–237, set out as a note under section 802 of this title.

Effective Date

Section effective on date that is 120 days after Dec. 17, 1993, see section 11 of Pub. L. 103–200, set out as an

Effective Date

of 1993 Amendment note under section 802 of this title.

Reference

Citations & Metadata

Citation

21 U.S.C. § 814

Title 21Food and Drugs

Last Updated

Apr 5, 2026

Release point: 119-73not60